digital currency what is it, searches

Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.Malaysia Airlines and Uzbekistan Airlines resumed code sharing agreement.Pan Xuan, Beijing Local Financial Administration: The total investable assets of households in Beijing's wealth management market are about 16 trillion yuan. Pan Xuan, deputy director of Beijing Local Financial Administration, pointed out in the global wealth management forum today that Beijing's wealth management industry has good basic conditions, huge market potential and strong demand, and has unique advantages in developing wealth management industry. Among them, on the supply side, the asset management scale of institutions such as bank wealth management, insurance asset management, Public Offering of Fund, private equity funds, trusts and brokerage asset management in Beijing exceeds 30 trillion yuan, accounting for nearly 30% of the country; At the same time, the scale of private equity and venture capital management is also the first in the country. On the demand side, the total investable assets of households in Beijing are about 16 trillion yuan, and the number of high-net-worth families, ultra-high-net-worth families and international ultra-high-net-worth families ranks first in the country.

Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

The Ministry of Industry and Information Technology decided to set up the Ministry of Artificial Intelligence Standardization Technical Committee, and the Ministry of Industry and Information Technology decided to set up the Ministry of Artificial Intelligence Standardization Technical Committee, numbered MIIT/TC1, which is mainly responsible for the compilation and revision of industry standards in the fields of artificial intelligence evaluation and testing, operation and maintenance, data set, basic hardware, software platform, large model, application maturity, application development management and artificial intelligence risk. The first Technical Committee of Artificial Intelligence Standardization of the Ministry of Industry and Information Technology consists of 41 members, and the secretariat is undertaken by China Information and Communication Research Institute.He ertai bought 199 million yuan and sold 155 million yuan in Shenzhen Stock Connect today. He ertai bought 199 million yuan and sold 155 million yuan today, with a turnover of 6.304 billion yuan and a turnover rate of 3.727%. After-hours data showed that the special seats of Shenzhen Stock Connect bought 199 million yuan and sold 155 million yuan.Hyundai Motor set up 200 million technology companies in Shanghai, including a number of AI-related businesses. According to Tianyancha App, Hyundai Kemo (Shanghai) Technology Co., Ltd. was recently established, with NOH YONG HO as the legal representative and a registered capital of 213 million RMB. Its business scope includes application system integration services in artificial intelligence industry, Internet of Things application services, data processing services, artificial intelligence basic software development, artificial intelligence application software development, artificial intelligence theory and algorithm software development, etc. According to shareholder information, the company is wholly owned by Hyundai Motor Co., Ltd.